CSF2 and congenital rubella syndrome: Yi et al. recently reported a clinical trial of CAR-T cells that tested the above modifications plus KO of GM-CSF.87 Although the trial was small in size, this combination might be useful in further reducing the risk of CRS, as there was no grade 3 or 4 CRS in any of the 3 enrolled patients.